FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to chimeric AAV capsids aimed at the central nervous system, to viral vectors containing them and to methods for using vectors for targeting the central nervous system. Invention also relates to chimeric AAV capsids aimed at oligodendrocytes, to viral vectors containing them and to methods of using vectors for targeting oligodendrocytes.
EFFECT: invention provides effective treatment of diseases associated with central nervous system.
36 cl, 1 tbl, 16 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
| ISOLATED MODIFIED VP1 CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 5 (AAV5), CAPSID AND VECTOR BASED ON IT | 2019 |
|
RU2751592C2 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
| GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
